Avidity Partners Management LP
- SEC CIK
- 0001791827
- Latest filing
- Aug 14, 2026
Holdings in Q3 2022
Holdings as of Sep 30, 2022, filed Nov 14, 2022. Long positions only; changes compare share counts with Q2 2022.
- Positions
- 96
- +14 vs. Q2 2022
- Portfolio value
- $4.60B
- +$241.5M (+5.5%) vs. Q2 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| LLYEli Lilly & Co | Stock | 1,007,000 | $325.6M | 7.1% | +397,000+65.1% | Added | History |
| UTHRUnited Therapeutics Corp | COM | 970,200 | $203.1M | 4.4% | +244,600+33.7% | Added | History |
| NBIXNeurocrine Biosciences Inc | Stock | 1,855,700 | $197.1M | 4.3% | +388,100+26.4% | Added | History |
| ARVNArvinas, Inc. | COM | 4,343,500 | $193.2M | 4.2% | +987,877+29.4% | Added | History |
| ARGXArgenx SE | SPONSORED ADR | 491,800 | $173.6M | 3.8% | −80,700−14.1% | Reduced | History |
| BIIBBiogen Inc. | COM | 600,000 | $160.2M | 3.5% | +159,434+36.2% | Added | History |
| VRTXVertex Pharmaceuticals Inc | Stock | 512,800 | $148.5M | 3.2% | −280,200−35.3% | Reduced | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 5,586,900 | $134.3M | 2.9% | +136,900+2.5% | Added | History |
| PRTAProthena Corp Public Ltd Co | SHS | 1,967,000 | $119.3M | 2.6% | +1,967,000 | New | History |
| State Street SPDR S&P Biotech ETF78464A870 | ETF | 1,480,000 | $117.4M | 2.6% | −395,000−21.1% | Reduced | – |
| ACHCAcadia Healthcare Company, Inc. | COM | 1,389,200 | $108.6M | 2.4% | +354,200+34.2% | Added | History |
| AKROAkero Therapeutics, Inc. | COM | 3,122,000 | $106.3M | 2.3% | +3,122,000 | New | History |
| SRPTSarepta Therapeutics, Inc. | COM | 948,200 | $104.8M | 2.3% | +948,200 | New | History |
| HUMHumana Inc | Stock | 212,000 | $102.9M | 2.2% | −200,300−48.6% | Reduced | History |
| BSXBoston Scientific Corp | Stock | 2,538,600 | $98.3M | 2.1% | +13,600+0.5% | Added | History |
| IMCRImmunocore Holdings plc | ADS | 2,079,100 | $97.6M | 2.1% | +729,100+54.0% | Added | History |
| KRTXKaruna Therapeutics, Inc. | COM | 431,800 | $97.1M | 2.1% | +227,230+111.1% | Added | History |
| ELVElevance Health, Inc. | Stock | 207,600 | $94.3M | 2.1% | −233,400−52.9% | Reduced | History |
| HZNPHorizon Therapeutics Public Ltd Co | SHS | 1,482,200 | $91.7M | 2.0% | −374,700−20.2% | Reduced | History |
| ZNTLZentalis Pharmaceuticals, Inc. | COM | 4,223,100 | $91.5M | 2.0% | +637,219+17.8% | Added | History |
| AVTRAvantor, Inc. | COM | 4,522,600 | $88.6M | 1.9% | −2,130,100−32.0% | Reduced | History |
| RAREUltragenyx Pharmaceutical Inc. | COM | 2,051,600 | $85.0M | 1.8% | +572,100+38.7% | Added | History |
| NTRANatera, Inc. | COM | 1,735,000 | $76.0M | 1.7% | +365,900+26.7% | Added | History |
| AXSMAxsome Therapeutics, Inc. | COM | 1,538,600 | $68.7M | 1.5% | +1,538,600 | New | History |
| CTLTCatalent, Inc. | COM | 940,000 | $68.0M | 1.5% | −15,000−1.6% | Reduced | History |
| ITCIIntra-Cellular Therapies, Inc. | COM | 1,402,500 | $65.3M | 1.4% | +626,996+80.9% | Added | History |
| SGENSeagen Inc. | COM | 445,500 | $61.0M | 1.3% | −104,500−19.0% | Reduced | History |
| BIOBio-Rad Laboratories, Inc. | CL A | 144,800 | $60.4M | 1.3% | +144,800 | New | History |
| ALNYAlnylam Pharmaceuticals, Inc. | COM | 288,500 | $57.7M | 1.3% | +288,500 | New | History |
| APLSApellis Pharmaceuticals, Inc. | COM | 844,000 | $57.6M | 1.3% | +629,000+292.6% | Added | History |
| NTLAIntellia Therapeutics, Inc. | COM | 999,100 | $55.9M | 1.2% | −126,094−11.2% | Reduced | History |
| IDYAIDEAYA Biosciences, Inc. | COM | 3,715,400 | $55.4M | 1.2% | +742,453+25.0% | Added | History |
| KZRKezar Life Sciences, Inc. | COM | 5,414,400 | $46.6M | 1.0% | +1,364,400+33.7% | Added | History |
| Bellus Health Inc New07987C204 | COM NEW | 4,346,700 | $45.9M | 1.0% | +81,700+1.9% | Added | – |
| RVMDRevolution Medicines, Inc. | COM | 2,321,200 | $45.8M | 1.0% | +996,200+75.2% | Added | History |
| Avidity Biosciences, Inc.05370A108 | COM | 2,600,000 | $42.5M | 0.9% | +519,800+25.0% | Added | – |
| JAZZJazz Pharmaceuticals plc | SHS USD | 318,300 | $42.4M | 0.9% | +256,300+413.4% | Added | History |
| ZLABZai Lab Ltd | ADR | 1,234,000 | $42.2M | 0.9% | +1,234,000 | New | History |
| ARWRArrowhead Pharmaceuticals, Inc. | COM | 1,255,374 | $41.5M | 0.9% | −183,625−12.8% | Reduced | History |
| PLRXPliant Therapeutics, Inc. | COM | 1,981,100 | $41.4M | 0.9% | +1,981,100 | New | History |
| DXCMDexcom Inc | COM | 467,600 | $37.7M | 0.8% | +467,600 | New | History |
| SYKStryker Corp | Stock | 184,700 | $37.4M | 0.8% | +184,700 | New | History |
| VERVVerve Therapeutics, Inc. | COM | 1,042,706 | $35.8M | 0.8% | +1,042,706 | New | History |
| ALTAltimmune, Inc. | COM NEW | 2,684,000 | $34.3M | 0.7% | −297,000−10.0% | Reduced | History |
| CNCCentene Corp | Stock | 432,400 | $33.6M | 0.7% | +432,400 | New | History |
| CRBUCaribou Biosciences, Inc. | COM | 3,172,600 | $33.5M | 0.7% | +222,600+7.5% | Added | History |
| AZNAstraZeneca PLC | SPONSORED ADR | 563,200 | $30.9M | 0.7% | −2,935,800−83.9% | Reduced | History |
| NGMNGM Biopharmaceuticals Inc | COM | 1,798,100 | $23.5M | 0.5% | +1,798,100 | New | History |
| DCPHDeciphera Pharmaceuticals, Inc. | COM | 1,191,800 | $22.0M | 0.5% | −8,200−0.7% | Reduced | History |
| PNTPOINT Biopharma Global Inc. | COM | 2,820,000 | $21.8M | 0.5% | +2,820,000 | New | History |
| PHATPhathom Pharmaceuticals, Inc. | COM | 1,906,800 | $21.1M | 0.5% | −13,000−0.7% | Reduced | History |
| COGTCogent Biosciences, Inc. | COM | 1,357,700 | $20.3M | 0.4% | +1,357,700 | New | History |
| NKTXNkarta, Inc. | COM | 1,414,082 | $18.6M | 0.4% | 00.0% | Unchanged | History |
| ONCBeOne Medicines Ltd. | ADR | 132,000 | $17.8M | 0.4% | +132,000 | New | History |
| SIBNSI-BONE, Inc. | COM | 996,700 | $17.4M | 0.4% | −3,300−0.3% | Reduced | History |
| GOSSGossamer Bio, Inc. | COM | 1,450,000 | $17.4M | 0.4% | +1,450,000 | New | History |
| CYTKCytokinetics Inc | COM NEW | 335,000 | $16.2M | 0.4% | +335,000 | New | History |
| ARQTArcutis Biotherapeutics, Inc. | COM | 794,500 | $15.2M | 0.3% | +794,500 | New | History |
| PCVXVaxcyte, Inc. | COM | 628,700 | $15.1M | 0.3% | +628,700 | New | History |
| ATECAlphatec Holdings, Inc. | COM NEW | 1,715,000 | $15.0M | 0.3% | 00.0% | Unchanged | History |
| KNTEKinnate Biopharma Inc. | COM | 1,212,611 | $14.5M | 0.3% | +1,212,611 | New | History |
| IOVAIovance Biotherapeutics, Inc. | COM | 1,382,900 | $13.2M | 0.3% | −9,400−0.7% | Reduced | History |
| ANTXAN2 Therapeutics, Inc. | COM | 742,630 | $12.9M | 0.3% | +54,300+7.9% | Added | History |
| IPSCCentury Therapeutics, Inc. | COM | 1,303,600 | $12.9M | 0.3% | +438,600+50.7% | Added | History |
| TMDXTransMedics Group, Inc. | COM | 300,000 | $12.5M | 0.3% | +300,000 | New | History |
| SGMOQSangamo Therapeutics, Inc | COM | 2,360,800 | $11.6M | 0.3% | +2,360,800 | New | History |
| STOKStoke Therapeutics, Inc. | COM | 891,100 | $11.4M | 0.2% | +891,100 | New | History |
| SPNESeaSpine Holdings Corp | COM | 2,010,000 | $11.4M | 0.2% | 00.0% | Unchanged | History |
| NSTGNS Wind Down Co., Inc. | COM | 698,200 | $8.92M | 0.2% | +698,200 | New | History |
| ERASErasca, Inc. | COM | 982,500 | $7.66M | 0.2% | −12,500−1.3% | Reduced | History |
| ALPNAlpine Immune Sciences, Inc. | COM | 998,600 | $7.19M | 0.2% | +350.0% | Added | History |
| SGRYSurgery Partners, Inc. | Stock | 267,600 | $6.26M | 0.1% | +267,600 | New | History |
| SYRSSyros Pharmaceuticals, Inc. | COM NEW | 900,000 | $5.80M | 0.1% | +900,000 | New | History |
| CMAXCareMax, Inc. | COM CL A | 755,329 | $5.36M | 0.1% | 00.0% | Unchanged | History |
| Medicus Sciences AcquisitionG5960S108 | CL A SHS | 520,000 | $5.15M | 0.1% | 00.0% | Unchanged | – |
| BCLS Acquisition CorpG0904B105 | COM CL A | 500,000 | $5.01M | 0.1% | 00.0% | Unchanged | – |
| LENZLENZ Therapeutics, Inc. | COM | 1,575,000 | $4.99M | 0.1% | +865,000+121.8% | Added | History |
| ARYDARYA Sciences Acquisition Corp IV | CL A | 500,000 | $4.96M | 0.1% | 00.0% | Unchanged | History |
| Panacea Acquisition Corp. IIG6882C106 | CL A SHS | 500,000 | $4.90M | 0.1% | 00.0% | Unchanged | – |
| CMPXCompass Therapeutics, Inc. | COM | 2,000,000 | $4.56M | 0.1% | 00.0% | Unchanged | History |
| EPIXESSA Pharma Inc. | COM NEW | 2,460,000 | $4.48M | 0.1% | 00.0% | Unchanged | History |
| OBIOOrchestra BioMed Holdings, Inc. | ORD SHS | 400,000 | $3.96M | 0.1% | 00.0% | Unchanged | History |
| CYTCyteir Therapeutics, Inc. | COM | 1,806,200 | $3.47M | 0.1% | −43,800−2.4% | Reduced | History |
| TNGXTango Therapeutics, Inc. | COM | 813,700 | $2.95M | 0.1% | +600.0% | Added | History |
| SCYXScynexis Inc | COM NEW | 1,140,600 | $2.74M | 0.1% | +181,076+18.9% | Added | History |
| DNADSocial Capital Suvretta Holdings Corp. IV | CLASS A ORD SHS | 200,000 | $1.96M | <0.1% | 00.0% | Unchanged | History |
| DNABSocial Capital Suvretta Holdings Corp. II | CLASS A ORD SHS | 200,000 | $1.96M | <0.1% | 00.0% | Unchanged | History |
| ONCSOncosec Medical Inc | COM | 2,945,000 | $1.44M | <0.1% | 00.0% | Unchanged | History |
| HYPRHyperfine, Inc. | COM CL A | 1,503,754 | $1.22M | <0.1% | 00.0% | Unchanged | History |
| ACIUAC Immune SA | SHS | 274,876 | $869.0K | <0.1% | +274,876 | New | History |
| Reunion Neuroscience Inc76134G103 | COM | 595,200 | $851.0K | <0.1% | +595,200 | New | – |
| WGSGeneDx Holdings Corp. | COMMON STOCK | 950,000 | $834.0K | <0.1% | 00.0% | Unchanged | History |
| PHASPhaseBio Pharmaceuticals Inc | COM | 4,361,365 | $768.0K | <0.1% | −43,635−1.0% | Reduced | History |
| SNCEScience 37 Holdings, Inc. | COM | 430,000 | $692.0K | <0.1% | 00.0% | Unchanged | History |
| Nuvation Bio Inc.67080N119 | *W EXP 07/07/202 | 99,999 | $18.0K | <0.1% | 00.0% | Unchanged | – |
| Medicus Sciences AcquisitionG5960S124 | *W EXP 02/12/202 | 57,770 | $1.00K | <0.1% | 00.0% | Unchanged | – |
Options (1)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| SPDR Ser Tr78464A900 | CALL | – | $321.4M |
Sold out since Q2 2022 (15)
Positions held at the end of Q2 2022 that are gone from this filing.
| Security | Class | Shares in Q2 2022 | Value in Q2 2022 | % of portfolio in Q2 2022 | History |
|---|---|---|---|---|---|
| JNJJohnson & Johnson | Stock | 900,200 | $159.8M | 3.7% | History |
| MCKMcKesson Corp | Stock | 388,800 | $126.8M | 2.9% | History |
| UNHUnitedHealth Group Inc | Stock | 242,200 | $124.4M | 2.9% | History |
| ABBVAbbVie Inc. | Stock | 755,000 | $115.6M | 2.7% | History |
| LEGNLegend Biotech Corp | SPONSORED ADS | 1,000,000 | $55.0M | 1.3% | History |
| ARK ETF Tr00214Q302 | GENOMIC REV ETF | 750,000 | $23.6M | 0.5% | – |
| VIRVir Biotechnology, Inc. | COM | 758,211 | $19.3M | 0.4% | History |
| NUVBNuvation Bio Inc. | COM CL A | 4,855,000 | $15.7M | 0.4% | History |
| XENEXenon Pharmaceuticals Inc. | COM | 450,000 | $13.7M | 0.3% | History |
| SSentinelOne, Inc. | CL A | 204,500 | $4.77M | 0.1% | History |
| ISEEIVERIC bio, Inc. | COM | 430,117 | $4.14M | 0.1% | History |
| Field Trip Health Ord31656R102 | COM | 2,976,000 | $2.50M | 0.1% | – |
| OTICOtonomy, Inc. | COM | 1,000,000 | $2.08M | <0.1% | History |
| PROKProkidney Corp. | CLASS A ORD SHS | 200,000 | $1.99M | <0.1% | History |
| AKLIAkili, Inc. | CLASS A ORD SHS | 200,000 | $1.98M | <0.1% | History |